Abstract
Introduction: NICE recommends the use of tumour profiling tests to guide adjuvant chemotherapy in Breast Cancer. The Oncotype DX score (Genomic Health) has superseded more traditional tools such as PREDICT in appropriate patients (ER+ve, HER2-ve, lymph node negative and with a Nottingham Prognostic Index [NPI] ≥3.4). The aim of this study was to see whether the introduction of Oncotype DX within our institution resulted in an overall reduction in rates of chemotherapy?
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
